EUVIMEDAvasta EUVIMED
CrossrefInfokaart

Can universal cervical length screening with vaginal progesterone for a short cervix reduce preterm birth? A systematic review and meta‐analyses

Mira Zethelius, Lina Bergman, Ann‐Catrin Ekelund, Cecilie Hongslo Vala, Bo Jacobsson, Pihla Kuusela, Ann Liljegren, Björn Lindkvist, Max Petzold, Petteri Sjögren, Ulla‐Britt Wennerholm, Tove Wikström

Acta Obstetricia et Gynecologica Scandinavica · 2026-08 · 105 (8) · 1420-1434

DOI: 10.1111/aogs.70253 ↗
AbstraktBibliograafilised andmed

Abstrakt

Abstract Introduction The global rate of preterm birth (PTB) is not declining, resulting in approximately one million deaths annually among children under five due to complications related to PTB. Universal cervical length screening followed by progesterone treatment in women with a short cervix has been proposed as a preventive strategy. We systematically assessed the accuracy of this approach in reducing the incidence of PTB and improving neonatal outcomes. Material and Methods We conducted a systematic literature search and meta‐analysis registered in PROSPERO (CRD42024605203). Medline, Embase, and the Cochrane Library were searched in October 2024 and updated in September 2025. Eligible studies included randomized controlled trials (RCTs), cohort studies, and systematic reviews comparing universal cervical length screening with vaginal ultrasound in mid‐trimester followed by progesterone treatment versus no screening in asymptomatic women with a singleton pregnancy. Outcomes of interest were any PTB, spontaneous PTB (sPTB), and neonatal outcomes. The certainty of evidence was assessed separately for RCTs and cohort studies using the GRADE approach. Results Two RCTs (1634 participants) and four cohort studies (425 735 participants) were included. Results from RCTs showed no statistically significant reduction in any PTB, sPTB, peri/neonatal mortality, or morbidity after screening versus no screening. In contrast, meta‐analyses of cohort studies demonstrated a significant reduction for any PTB < 37 weeks; adjusted odds ratio 0.87, 95% confidence interval (CI) 0.78–0.98, and sPTB < 37 weeks; relative risk 0.82, 95% CI 0.70–0.96. Meta‐analyses of cohort studies also demonstrated a significant reduction in sPTB < 34 and

Teadmised, mis sobivad teie tööga.

Tasuta alustamisest ja isiklikust kirjanduse otsingust kuni täieliku Research Suite’ini.

Vaata pakette →

Kas kõik kirjastajate täistekstid on kaasatud?

Ei. Bibliograafilised kirjed, kokkuvõtted ja täistekstid on erinevad sisud. See, kas täistekst on saadaval, sõltub allikast, Open Accessist ja teie olemasolevatest litsentsidest. EUVIMED-i pakett ei asenda täiendavaid kirjastajaõigusi.

Vaata pakette →